Jane Street’s Elevation Oncology ELEV Stock Holding History

Jane Street’s Portfolio ELEV Stock Details ELEV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-255,443	Closed	-$93.8K	–	10975
2025 Q2	$93.8K	Buy	255,443 +210,252	+465%	+$70.2K	﹤0.01%	8978
2025 Q1	$11.7K	Sell	45,191 -25,692	-36%	-$14.7K	﹤0.01%	9192
2024 Q4	$39.9K	Buy	70,883 +41,215	+139%	+$24.3K	﹤0.01%	9026
2024 Q3	$17.8K	Sell	29,668 -20,452	-41%	-$30.3K	﹤0.01%	9308
2024 Q2	$135K	Sell	50,120 -28,780	-36%	-$108K	﹤0.01%	8623
2024 Q1	$405K	Buy	+78,900	New	+$256K	﹤0.01%	7064
2023 Q2	–	Sell	-10,449	Closed	-$19.9K	–	8871
2023 Q1	$19.9K	Buy	+10,449	New	+$13.5K	﹤0.01%	8649
2022 Q1	–	Sell	-20,892	Closed	-$126K	–	10448
2021 Q4	$126K	Buy	+20,892	New	+$144K	﹤0.01%	9113

Other funds holding ELEV

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Jane Street's ELEV Position: Q3 2025 in Review

Jane Street sold out of Elevation Oncology (ELEV) in Q3 2025, closing a stake of 255,443 shares — an estimated $93.8K sold.

Jane Street first reported a position in ELEV in Q4 2021 and held it in 8 quarters. The position peaked at $405K in Q1 2024. 1 fund tracked by Wall St. Rank holds ELEV as of Q3 2025.

Jane Street reported no remaining Elevation Oncology position as of Q3 2025 after selling out during the quarter.
Jane Street sold 255,443 Elevation Oncology shares in Q3 2025, an estimated $93.8K.
Jane Street first reported a position in Elevation Oncology in Q4 2021 and held it in 8 quarters.
Jane Street's Elevation Oncology position peaked at $405K in Q1 2024.
1 fund tracked by Wall St. Rank held Elevation Oncology as of Q3 2025.

Based on Jane Street's 13F filing for Q3 2025, filed 14 Nov 2025.